UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

Mitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases

Annual review of pharmacology and toxicology, 2016-01, Vol.56 (1), p.229-249

2016

Volltextzugriff (PDF)

PDE5 inhibition rescues mitochondrial dysfunction and angiogenic responses induced by Akt3 inhibition by promotion of PRC expression

The Journal of biological chemistry, 2020-12, Vol.295 (52), p.18091-18104

2020

Volltextzugriff (PDF)

AKT3 controls mitochondrial biogenesis and autophagy via regulation of the major nuclear export protein CRM‐1

The FASEB journal, 2014-01, Vol.28 (1), p.395-407

2014

Volltextzugriff (PDF)

Profiling the Reproductive Toxicity of Chemicals from Multigeneration Studies in the Toxicity Reference Database

Toxicological sciences, 2009-07, Vol.110 (1), p.181-190

2009

Volltextzugriff (PDF)

Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans

Frontiers in pharmacology, 2016-06, Vol.7, p.135-135

2016

Volltextzugriff (PDF)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

HemaSphere, 2023-08, Vol.7 (S3), p.e56956b1

2023

Volltextzugriff (PDF)

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

HemaSphere, 2023-08, Vol.7 (S3), p.e19161da

2023

Volltextzugriff (PDF)

Safety and efficacy of murine PVSRIPO plus anti-PD-1 immune checkpoint inhibitor (ICI) in a melanoma tumor model

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2560-2560

2021

Volltextzugriff (PDF)

5‐HT1F receptor‐mediated mitochondrial biogenesis for the treatment of Parkinson's disease

British journal of pharmacology, 2018-01, Vol.175 (2), p.348-358

2018

Volltextzugriff (PDF)

Schematic diagram of the neural protective role of IMMH004 after TGCI/R Pharmacological Induction of Mitochondrial Biogenesis using the β2‐Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury

The FASEB journal, 2018-04, Vol.32, p.824.8-824.8

2018

Volltextzugriff (PDF)

Schematic diagram of the neural protective role of IMMH004 after TGCI/R Pharmacological Induction of Mitochondrial Biogenesis using the β 2 ‐Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury

The FASEB journal, 2018-04, Vol.32 (S1)

2018

Volltextzugriff (PDF)

5-HT 1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease

British journal of pharmacology, 2018-01, Vol.175 (2), p.348-358

2018

Volltextzugriff (PDF)

AML-516 KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S308-S309

2023

Volltextzugriff (PDF)

POSTER: AML-516 KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S171-S171

2023

Volltextzugriff (PDF)

Enhanced Mitochondrial Biogenesis for the Treatment of Spinal Cord Injury

The FASEB journal, 2017-04, Vol.31 (S1)

2017

Volltextzugriff (PDF)

AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S304-S305

2023

Volltextzugriff (PDF)

POSTER: AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S168-S168

2023

Volltextzugriff (PDF)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

HemaSphere, 2023-08, Vol.7, p.n/a

2023

Volltextzugriff (PDF)

Characterization of copper voids in damascene processes

IEEE transactions on semiconductor manufacturing, 2004-11, Vol.17 (4), p.597-602

2004

Volltextzugriff (PDF)

PDE5 inhibition rescues mitochondrial dysfunction and angiogenic responses induced by Akt3 inhibition by promotion of PRC expression

The Journal of biological chemistry, 2020-12, Vol.295 (52), p.18091

2020

Volltextzugriff (PDF)

The role of Akt3 in the vascular endothelium

Corum, Daniel G

2014

Volltextzugriff (PDF)

Characterization of Phosphate and Arsenate Adsorption onto Keggin-Type Al30 Cations by Experimental and Theoretical Methods

Inorganic chemistry, 2015-09, Vol.54 (17), p.8367-8374

2015

Volltextzugriff (PDF)

PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration

American Journal of Physiology: Cell Physiology, 2004-01, Vol.286 (1), p.C153-C163

2004

Volltextzugriff (PDF)

Characterization of Phosphate and Arsenate Adsorption onto Keggin-Type Al 30 Cations by Experimental and Theoretical Methods

Inorganic chemistry, 2015-09, Vol.54 (17), p.8367-8374

2015

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(33)

Publikationsform

Sprache

Englisch
(34)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(10)
Life Sciences & Biomedicine
(8)
Animals
(5)
Biochemistry & Molecular Biology
(3)
Cell Biology
(3)
Humans
(3)
Male
(3)
Mice
(3)
Organelle Biogenesis
(3)
Pharmacology & Pharmacy
(3)
Acute Myeloid Leukemia
(2)
Analysis
(2)
Angiogenesis
(2)
Endothelial Cells
(2)
Gene Expression Regulation
(2)
Health Aspects
(2)
High Performance Liquid Chromatography
(2)
Measurement
(2)
Menin Inhibitor
(2)
Mitochondria - Drug Effects
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases

PDE5 inhibition rescues mitochondrial dysfunction and angiogenic responses induced by Akt3 inhibition by promotion of PRC expression

AKT3 controls mitochondrial biogenesis and autophagy via regulation of the major nuclear export protein CRM‐1

Profiling the Reproductive Toxicity of Chemicals from Multigeneration Studies in the Toxicity Reference Database

Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Safety and efficacy of murine PVSRIPO plus anti-PD-1 immune checkpoint inhibitor (ICI) in a melanoma tumor model

5‐HT1F receptor‐mediated mitochondrial biogenesis for the treatment of Parkinson's disease

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1‐MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Schematic diagram of the neural protective role of IMMH004 after TGCI/R Pharmacological Induction of Mitochondrial Biogenesis using the β2‐Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury

Schematic diagram of the neural protective role of IMMH004 after TGCI/R Pharmacological Induction of Mitochondrial Biogenesis using the β 2 ‐Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury

5-HT 1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease

AML-516 KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia

POSTER: AML-516 KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia

Enhanced Mitochondrial Biogenesis for the Treatment of Spinal Cord Injury

AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML

POSTER: AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Characterization of copper voids in damascene processes

PDE5 inhibition rescues mitochondrial dysfunction and angiogenic responses induced by Akt3 inhibition by promotion of PRC expression

The role of Akt3 in the vascular endothelium

Characterization of Phosphate and Arsenate Adsorption onto Keggin-Type Al30 Cations by Experimental and Theoretical Methods

PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration

Characterization of Phosphate and Arsenate Adsorption onto Keggin-Type Al 30 Cations by Experimental and Theoretical Methods

Suchergebnisse filtern